With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and ...

With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...

Firms that advise generics businesses reflect on whether they’re seeing more aggressive tactics from innovators and how ...

SHANGHAI, Nov. 7 (Xinhua) -- In the vast and intricately designed National Exhibition and Convention Center (Shanghai), where ...

In April 2021, Novartis AG announced a collaboration with Artios Pharma. This collaboration was made to improve both companies’ discovery platforms, leverage their knowledge, and improve the potential ...

Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160 for immune-related conditions; $150M ...

BC Partners Real Estate’s first investment in Spain was in partnership with Freo Group to acquire the Spanish headquarters of ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

Siponimod, branded by Swiss-drug major Novartis as Mayzent, is reportedly the first oral treatment indicated for active SPMS in adults. Novartis, while announcing its FDA approval for Mayzent in 2019, ...

Chemists synthesized a highly complex natural molecule through a revolutionary strategy of functionalizing normally inert carbon-hydrogen ...

Earlier this month, Firefly Neuroscience completed successful research collaborations with Takeda Pharmaceutical (NYSE:TAK) ...